#4-81E. Guiding Reproductive Journeys: The Clinician as a Sherpa in Immune-Mediated Diseases (Lancet Rheumatol, 2026)

Have you ever struggled with the frustrating discrepancies between conservative drug labels and evidence-based clinical guidelines when counseling patients with immune-mediated diseases about their pregnancy and family planning? Today, we delve into a pivotal commentary that highlights the critical evidence gaps and systemic barriers surrounding medication use before, during, and after pregnancy for individuals living with immune-mediated long-term conditions. The core message of this paper strongly advocates for a paradigm shift: moving away from isolated, individual physician judgments toward a robust, multidisciplinary framework of genuine shared decision-making. Critically, when evaluating this manuscript, readers must keep in mind that it is not an original research article providing novel clinical data; rather, it serves as a commission announcement primarily focused on the European Union healthcare system. Nevertheless, this perspective remains profoundly relevant and impactful for medical professionals worldwide. It challenges clinicians to reconsider their everyday roles as clinical "sherpas"—expertly guiding patients through the highly unpredictable terrain of family planning amid significant clinical uncertainty. Ultimately, embracing this collaborative approach empowers us to better support our patients' complex reproductive journeys and transform daily clinical practice.

Citation: Schreiber K, Clark A, Andreoli L. Announcing The Lancet Rheumatology commission on reproductive health and family planning in immune-mediated long-term conditions: empowering special reproductive journeys. The Lancet Rheumatology. 2026. DOI: 10.1016/S2665-9913(26)00157-8

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.